Rhabdomyosarcoma historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
===Landmark Events in the Development of Treatment Strategies=== | ===Landmark Events in the Development of Treatment Strategies=== | ||
*Improvement of knowledge and treatment of rhabdomyosarcoma was mostly came by cooperative group studies because this was not possible for a single institution or regional centers to conduct studies about biology and treatment of | *Improvement of knowledge and treatment of [[rhabdomyosarcoma]] was mostly came by cooperative group studies because this was not possible for a single institution or regional centers to conduct studies about [[biology]] and treatment of [[rhabdomyosarcoma]] due to variable nature and uncommon occurrence of [[tumors]].<ref name="pmid21357792">{{cite journal| author=Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX et al.| title=Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 10 | pages= 1304-11 | pmid=21357792 | doi=10.1200/JCO.2010.29.4611 | pmc=3083998 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21357792 }} </ref> | ||
==References== | ==References== | ||
Revision as of 17:06, 10 January 2019
|
Rhabdomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhabdomyosarcoma historical perspective On the Web |
|
American Roentgen Ray Society Images of Rhabdomyosarcoma historical perspective |
|
Risk calculators and risk factors for Rhabdomyosarcoma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Rhabdomyosarcoma is considered as the most common malignant soft tissue tumors and the third most common extracranial solid tumors during childhood. Rhabdomyosarcoma was firstly described by Weber (German physician) in 1854. In 1946, distinct morphology, histology, and classification of rhabdomyosarcoma was understood by Arthur Stout. Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.
Historical Perspective
Discovery
- Rhabdomyosarcoma is derived from two Greek words, Rhabdo means rod shape and myo means muscle.[1]
- Rhabdomyosarcoma was firstly described by Weber (German physician) in 1854.
- In 1946, distinct morphology, histology, and classification of rhabdomyosarcoma was understood by Arthur Stout.[2]
- Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.[3]
- Intergroup Rhabdomyosarcoma Study Group (IRSG) conducted thirty years of investigation about rhabdomyosarcoma.
Landmark Events in the Development of Treatment Strategies
- Improvement of knowledge and treatment of rhabdomyosarcoma was mostly came by cooperative group studies because this was not possible for a single institution or regional centers to conduct studies about biology and treatment of rhabdomyosarcoma due to variable nature and uncommon occurrence of tumors.[4]
References
- ↑ STOUT AP (1946). "Rhabdomyosarcoma of the skeletal muscles". Ann Surg. 123: 447–72. PMID 21018470.
- ↑ Stout AP (1946). "Rhabdomyosarcoma of the Skeletal Muscles". Ann Surg. 123 (3): 447–72. PMC 1803493. PMID 17858752.
- ↑ El Demellawy D, McGowan-Jordan J, de Nanassy J, Chernetsova E, Nasr A (2017). "Update on molecular findings in rhabdomyosarcoma". Pathology. 49 (3): 238–246. doi:10.1016/j.pathol.2016.12.345. PMID 28256213.
- ↑ Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX; et al. (2011). "Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group". J Clin Oncol. 29 (10): 1304–11. doi:10.1200/JCO.2010.29.4611. PMC 3083998. PMID 21357792.